Explanipedia

A Rare Cause of Internal Jugular Vein Thrombosis: Deep Tissue Massage Open

Matthew R. Sanborn, Mark J. Koury, A. Maity, Zonera Ali · 2025

Deep tissue massage is not a well-established cause of internal jugular vein thrombosis. This case emphasizes the importance of obtaining a thorough patient history to assess for uncommon traumatic causes of internal jugular vein thrombosi…

Rare Diagnosis of Localized Breast Amyloidosis in the Setting of Lymphoplasmacytic Lymphoma Open

Mark J. Koury, Karthik Shankar, Walter M. Klein, Zonera Ali · 2025

Breast amyloidosis is a rare diagnosis that should be considered when patients present with a breast mass. This case emphasizes the importance of a full diagnostic workup when breast amyloidosis is diagnosed to rule out systemic amyloidosi…

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease Open

Volker H. Haase, Tetsuhiro Tanaka, Mark J. Koury · 2024

Anemia is a hallmark of chronic kidney disease (CKD), worsens with disease progression, and profoundly affects a patient's well-being. Major pathogenic factors are inadequate kidney erythropoietin (EPO) production and absolute and function…

#2063 Safety and efficacy of vadadustat vs darbepoetin alfa in patients on maintenance dialysis by prespecified subgroups of baseline ESA dose Open

Glenn M. Chertow, Alan G. Jardine, Steven K. Burke, Wei Luo, Todd Minga , et al. · 2024

Background and Aims Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in Europe, Australia, Japan for the treatment of anemia in patients with dialysis-dependent (DD)-CKD. In the INNO2VATE global phase 3 …

Sickle cell disease today: a 75-year journey from “first molecular disease” to “first gene-editing therapy” Open

M. SHAPIRA, Mark J. Koury, Irene Roberts · 2024

No abstract available.

Table of Contents Open

Gerhard Malnic, Adriana C. C. Girardi, Rolf A.K. Stahl, Elion Hoxha, William Couser , et al. · 2023

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis Open

Mark J. Sarnak, Rajiv Agarwal, Neil Boudville, Pradip C P Chowdhury, Kai‐Uwe Eckardt , et al. · 2023

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two rand…

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease Open

Mark J. Koury, Rajiv Agarwal, Glenn M. Chertow, Kai‐Uwe Eckardt, Steven Fishbane , et al. · 2022

Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical tri…

EpoR stimulates rapid cycling and larger red cells during mouse and human erythropoiesis Open

Daniel Hidalgo, Jacob Bejder, Ramona Pop, Kyle Gellatly, Yung Hwang , et al. · 2021

The erythroid terminal differentiation program couples sequential cell divisions with progressive reductions in cell size. The erythropoietin receptor (EpoR) is essential for erythroblast survival, but its other functions are not well char…

MO541HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH NON--DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE Open

Mark J. Koury, Pablo E. Pérgola, Prabir Roy‐Chaudhury, Youssef M.K. Farag, Dennis Vargo , et al. · 2021

Background and Aims Vadadustat is a small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases under development to treat anemia associated with chronic kidney disease (CKD). The vadadustat phase 3 program includes four effic…

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis Open

Kai‐Uwe Eckardt, Rajiv Agarwal, Ahmad Aswad, Ahmed Awad, Geoffrey A. Block , et al. · 2021

Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. (Funded by Akebia Therapeuti…

Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD Open

Glenn M. Chertow, Pablo E. Pérgola, Youssef M.K. Farag, Rajiv Agarwal, Susan Arnold , et al. · 2021

Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia T…

The Erythropoietin Receptor Stimulates Rapid Cycling and Formation of Larger Red Cells During Mouse and Human Erythropoiesis Open

Daniel Hidalgo, Jacob Bejder, Ramona Pop, Kyle Gellatly, S. Maxwell Scalf , et al. · 2020

Erythroid terminal differentiation entails cell divisions that are coupled to progressive decreases in cell size. EpoR signaling is essential for the survival of erythroid precursors, but it is unclear whether it has other functions in the…

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials Open

Kai‐Uwe Eckardt, Rajiv Agarwal, Youssef M.K. Farag, Alan G. Jardine, Zeeshan Khawaja , et al. · 2020

Background Erythropoiesis-stimulating agents (ESAs) are currently the mainstay of treatment for anaemia of chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimu…

<i>TG-Interacting Factor 1</i> expression quantitatively impacts survival in acute myeloid leukemia Open

Yan Ling, Julie A. Means‐Powell, Danko Martincic, Vladimir D. Kravtsov, Yu Shyr , et al. · 2020

Applying transcriptional profiling analysis to myeloblasts from 59 adult patients with acute myeloid leukemia (AML) treated at our institution, we found that expression of the three-amino acid loop extension (TALE) homeobox gene TG-Interac…

A multiscale model to design therapeutic strategies that overcome drug resistance to tyrosine kinase inhibitors in multiple myeloma Open

Anass Bouchnita, Vitaly Volpert, Mark J. Koury, Andreas Hellander · 2019

Transition to 37°C reveals importance of NADPH in mitigating oxidative stress in stored RBCs Open

Aline Roch, Nicholas J. Magon, Jessica Maire, Cacang Suarna, Anita Ayer , et al. · 2019

The RBC storage lesion is a multiparametric response that occurs during storage at 4°C, but its impact on transfused patients remains unclear. In studies of the RBC storage lesion, the temperature transition from cold storage to normal bod…

Epo reprograms the epigenome of erythroid cells Open

Andrea A. Perreault, Mary Lauren Benton, Mark J. Koury, Stephen J. Brandt, Bryan J. Venters · 2017

A Hybrid Computation Model to Describe the Progression of Multiple Myeloma and Its Intra-Clonal Heterogeneity Open

Anass Bouchnita, Fatima-Ezzahra Belmaati, Rajae Aboulaïch, Mark J. Koury, Vitaly Volpert · 2017

Multiple myeloma (MM) is a genetically complex hematological cancer that is characterized by proliferation of malignant plasma cells in the bone marrow. MM evolves from the clonal premalignant disorder monoclonal gammopathy of unknown sign…

Preventing oxidative reactions during red blood cell storage for transfusion Open

Aline Roch, Nicholas J. Magon, Mark J. Koury, M Schapira, Beat A. Imhof · 2016

Red blood cell transfusion is life-saving for severely ill and injured patients. However, transfusion can increase mortality due to the prolonged storage time of blood. Previous studies have indicated that red blood cells undergo structura…

Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis Open

Anass Bouchnita, Nathalie Eymard, Tamara K. Moyo, Mark J. Koury, Vitaly Volpert · 2016

Multiple myeloma (MM) infiltrates bone marrow and causes anemia by disrupting erythropoiesis, but the effects of marrow infiltration on anemia are difficult to quantify. Marrow biopsies of newly diagnosed MM patients were analyzed before a…

Tracking erythroid progenitor cells in times of need and times of plenty Open

Mark J. Koury · 2015

Anaemia in kidney disease: harnessing hypoxia responses for therapy Open

Mark J. Koury, Volker H. Haase · 2015

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial Open

Peter Van Buren, Julia B. Lewis, Jamie P. Dwyer, Tom Greene, John P. Middleton , et al. · 2015

FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD) Open

Negoi Dana, Jamie P. Dwyer, Julia B. Lewis, Kausik Umanath, Stephen Z. Fadem , et al. · 2015

SP657GASTROINTESTINAL SAFETY AND TOLERABILITY OF FERRIC CITRATE IN PATIENTS WITH ESRD ON DIALYSIS: A POOLED ANALYSIS Open

Gil Chernin, Ingrid J. Chang, Udayan Bhatt, Andrea Núñez Ortiz, Sean Barry , et al. · 2015

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD Open

Kausik Umanath, Diana Jalal, Barbara Greco, Ebele M. Umeukeje, Efrain Reisin , et al. · 2015

Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic …

Dysfunctional neobladder causing pulmonary toxicity after combination chemotherapy for lymphoma Open

Ramya Thota, Chirayu Shah, Travis D. Richardson, Mark J. Koury · 2015

A 75-year-old man with transitional cell bladder carcinoma status post cystoprostatectomy with neobladder creation from the sigmoid colon was diagnosed with Stage IVA diffuse large B-cell lymphoma involving the kidney in an evaluation for …

Initiation of erythropoiesis by BFU-E cells Open

Anass Bouchnita, Nathalie Eymard, Mark J. Koury, Vitaly Volpert · 2015

International audience

Normal erythropoiesis and development of multiple myeloma Open

Anass Bouchnita, Nathalie Eymard, Mark J. Koury, Tamara K. Moyo, Vitaly Volpert · 2015

\nWe develop a hybrid multi-scale model of normal and pathological erythropoiesis, the process of red blood cell production in the bone marrow. Cells are described by a soft sphere model. They can move, divide and die by apoptosis. Their f…

Mark J. Koury YOU? Author Swipe